Skip to Main Content

Dubai Health Authority - هيئة الصحة دبي

Text Resize

Use the buttons below to increase or decrease the text size

Contrast switch

Use the toggle below to switch the contrast.

SCREEN READER

Listen to the content of the page by clicking play on ReadSpeaker.

Access

To discover more about accessibility, view our Accessibility Options here

Dubai Health Authority - هيئة الصحة دبي

Text Resize

Use the buttons below to increase or decrease the text size

Contrast switch

Use the toggle below to switch the contrast.

SCREEN READER

Listen to the content of the page by clicking play on ReadSpeaker.

Access

To discover more about accessibility, view our Accessibility Options here

Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)

25 Jun 2025

Reference: CIR-2025-00000111


To all Health facilities and healthcare practitioners in Dubai's private health sector

 

Referring to the above subject, DHA notifies all health facilities regarding the circulars issued by the MOHAP for perusal and adherence to what is stated.

Circular No. 06  for the year 2025 Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)

 

Thanks in advance for your good co-operation

 

Drug Control Section

Health Regulation Sector

DHA

Do you find this Content helpful?

Close
Phone